Viridis Chemical - Chapter 11 Plan Terms

Viridis Chemical's Chapter 11 plan of liquidation distributes the proceeds of a Section 363 sale of substantially all of its assets to stalking-horse purchaser BioUrja Capital, LLC — for $750,000 in cash, a contingent $1.5 million escrow, and the assumption of certain liabilities (including cure costs). The plan is facilitated by a concession from EIV, the Debtors' largest secured noteholder and equity holder, which agreed to waive its entire approximately $12.2 million secured notes claim in exchange for a release of the Debtors' claims against it and a mutual release between EIV and co-noteholder IFG. EIV's waiver unlocks value to pay administrative, professional, and priority claims in full and to lift IFG's recovery to roughly $125,000–$150,000 (from an estimated $24,000 in a Chapter 7 scenario in which EIV would retain and collect on its claim). The contingent $1.5 million escrow funds the Lien Release Cash Pool reserved for statutory mechanic's lien claimants, payable only if 100% of those claimants consent and all liens on BioUrja Renewables' Peoria property are released to the Purchaser's satisfaction on or before July 10, 2026. Thomas A. Howley of Howley Law PLLC will serve as Wind Down Administrator.

Plan Terms

Overview

Company Background

Corporate Structure

Capital Structure

  • The Debtors entered the Chapter 11 Cases with approximately $17.3 million in funded debt and obligations, consisting of approximately $13.5 million in aggregate principal (the Secured Notes and the Subordinated Unsecured Notes) plus accrued and unpaid interest.
  • Sale Process and 363 Asset Sale

    EIV Settlement

    CMA Fee Compromise

    Statutory Lien Claims and Lien Release

    Chapter 11 Plan of Liquidation

    Wind Down Administrator

    Releases

    Exculpation

    Classification and Treatment of Claims and Interests

    Injunction

    Confirmation and Voting